EPS8L1

Across TCGA pan-cancer cohorts, EPS8L1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated EPS8L1 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher EPS8L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EPS8L1 expression acts as an unfavorable survival marker.

UCS, DLBC, and STAD are the cancer types where EPS8L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.144	0.698	<.001	36	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
STAD	OS	Median	II,III,IV	0.184	0.710	.001	18	view →
SARC	OS	Median	All	0.126	0.860	<.001	12	view →
READ	DFS	Median	All	0.084	0.845	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

EPS8L1–UCS (OS)

Open the UCS breakdown →